nach oben

Pediatric Radiology

Erschienen in:

01.04.2018 | Minisymposium: Fetal/neonatal imaging

Have we done our last amniocentesis? Updates on cell-free DNA for Down syndrome screening

verfasst von: Kathryn J. Gray, Louise E. Wilkins-Haug

Erschienen in: Pediatric Radiology | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Prenatal aneuploidy screening changed significantly in 2012 when cell-free fetal deoxyribonucleic acid (DNA) was introduced as a noninvasive prenatal test. A noninvasive prenatal test detects cell free fragments of fetal DNA from the placenta circulating in maternal blood that coexist with cell-free DNA (cfDNA) of maternal origin. Using next-generation sequencing, the noninvasive prenatal test compares maternal and fetal cfDNA ratios for chromosomes of interest (i.e., 21, 18, 13, X, and Y) to assess chromosomal aneuploidy. Compared to traditional screening using ultrasound and serum markers, the noninvasive prenatal test has superior test characteristics, including a higher detection rate and positive predictive value, and a lower false-positive rate. The noninvasive prenatal test is already used for primary screening in high-risk women and is rapidly expanding to all women. Given its increasing use, understanding the noninvasive prenatal test’s limitations is critical. Discordant results (i.e. noninvasive prenatal test is positive for aneuploidy with a normal fetal karyotype) can occur because of biological processes such as aneuploidy confined to the placenta, a vanished twin, maternal aneuploidy or maternal cancer. Use of the noninvasive prenatal test for screening beyond the most common aneuploidies is not recommended. The noninvasive prenatal test is a major advance in prenatal aneuploidy screening but it is not diagnostic and does not replace invasive testing (i.e. chorionic villous sampling or amniocentesis) for confirmation of fetal chromosomal disorders.

Bianchi DW, Wataganara T, Lapaire O et al (2006) Fetal nucleic acids in maternal body fluids: an update. Ann N Y Acad Sci 1075:63–73CrossRefPubMed

American College of Obstetricians and Gynecologists (2016) Practice bulletin no. 163: screening for fetal aneuploidy. Obstet Gynecol 127:e123–e137CrossRef

American College of Obstetricians and Gynecologists (2015) Committee opinion, no. 640, cell-free DNA screening for fetal aneuploidy. Obstet Gynecol 126:e31–e37CrossRef

Society for Maternal-Fetal Medicine (SMFM) Publications Committee (2015) SMFM statement: clarification of recommendations regarding cell-free DNA aneuploidy screening. Am J Obstet Gynecol 213:753–754CrossRef

Malone FD, Canick JA, Ball RH et al (2005) First-trimester or second-trimester screening, or both, for Down’s syndrome. N Engl J Med 353:2001–2011CrossRefPubMed

Cuckle HS, Malone FD, Wright D et al (2008) Contingent screening for Down syndrome — results from the FaSTER trial. Prenat Diagn 28:89–94CrossRefPubMed

Desai RG, Creger WP (1963) Maternofetal passage of leukocytes and platelets in man. Blood 21:665–673PubMed

Mandel P, Metais P (1948) Les acides nucléiques du plasma sanguin chez l'homme. [The nucleic acids of blood plasma in humans]. C R Seances Soc Biol Fil 142:241–243PubMed

Cai X, Janku F, Zhan Q, Fan J-B (2015) Accessing genetic information with liquid biopsies. Trends Genet 31:564–575CrossRefPubMed

10.

Truszewska A, Foroncewicz B, Pączek L (2016) The role and diagnostic value of cell-free DNA in systemic lupus erythematosus. Clin Exp Rheumatol 35:330–336PubMed

11.

Volik S, Alcaide M, Morin RD, Collins C (2016) Cell-free DNA (cfDNA): clinical significance and utility in cancer shaped by emerging technologies. Mol Cancer Res 14:898–908CrossRefPubMed

12.

Lo YM, Corbetta N, Chamberlain PF et al (1997) Presence of fetal DNA in maternal plasma and serum. Lancet 350:485–487CrossRefPubMed

13.

Maron JL, Bianchi DW (2007) Prenatal diagnosis using cell-free nucleic acids in maternal body fluids: a decade of progress. Am J Med Genet C Semin Med Genet 145C:5–17CrossRefPubMed

14.

Canick JA, Palomaki GE, Kloza EM et al (2013) The impact of maternal plasma DNA fetal fraction on next generation sequencing tests for common fetal aneuploidies. Prenat Diagn 33:667–674CrossRefPubMed

15.

Guibert J, Benachi A, Grebille A-G et al (2003) Kinetics of SRY gene appearance in maternal serum: detection by real time PCR in early pregnancy after assisted reproductive technique. Hum Reprod 18:1733–1736CrossRefPubMed

16.

Lo YM, Zhang J, Leung TN et al (1999) Rapid clearance of fetal DNA from maternal plasma. Am J Hum Genet 64:218–224CrossRefPubMedPubMedCentral

17.

Yu SCY, Lee SWY, Jiang P et al (2013) High-resolution profiling of fetal DNA clearance from maternal plasma by massively parallel sequencing. Clin Chem 59:1228–1237CrossRefPubMed

18.

Pergament E, Cuckle H, Zimmermann B et al (2014) Single-nucleotide polymorphism-based noninvasive prenatal screening in a high-risk and low-risk cohort. Obstet Gynecol 124:210–218CrossRefPubMedPubMedCentral

19.

Chitty LS, Finning K, Wade A et al (2014) Diagnostic accuracy of routine antenatal determination of fetal RHD status across gestation: population based cohort study. BMJ 349:g5243CrossRefPubMedPubMedCentral

20.

Chan KCA, Zhang J, Hui ABY et al (2004) Size distributions of maternal and fetal DNA in maternal plasma. Clin Chem 50:88–92CrossRefPubMed

21.

Chiu RWK, Chan KCA, Gao Y et al (2008) Noninvasive prenatal diagnosis of fetal chromosomal aneuploidy by massively parallel genomic sequencing of DNA in maternal plasma. Proc Natl Acad Sci U S A 105:20458–20463CrossRefPubMedPubMedCentral

22.

Palomaki GE, Kloza EM, Lambert-Messerlian GM et al (2011) DNA sequencing of maternal plasma to detect Down syndrome: an international clinical validation study. Genet Med 13:913–920CrossRefPubMed

23.

Palomaki GE, Messerlian GM, Halliday JV (2017) Prenatal screening for common aneuploidies using cell-free DNA. In: Wilkins-Haug L (ed) UpToDate. http://www.uptodate.com/contents/prenatal-screening-for-common-aneuploidies-using-cell-free-dna. Accessed 10 Jan 2017

24.

Gil MM, Quezada MS, Revello R et al (2015) Analysis of cell-free DNA in maternal blood in screening for fetal aneuploidies: updated meta-analysis. Ultrasound Obstet Gynecol 45:249–266CrossRefPubMed

25.

Mazloom AR, Džakula Ž, Oeth P et al (2013) Noninvasive prenatal detection of sex chromosomal aneuploidies by sequencing circulating cell-free DNA from maternal plasma. Prenat Diagn 33:591–597CrossRefPubMed

26.

Samango-Sprouse C, Banjevic M, Ryan A et al (2013) SNP-based non-invasive prenatal testing detects sex chromosome aneuploidies with high accuracy. Prenat Diagn 33:643–649CrossRefPubMedPubMedCentral

27.

Hooks J, Wolfberg AJ, Wang ET et al (2014) Non-invasive risk assessment of fetal sex chromosome aneuploidy through directed analysis and incorporation of fetal fraction. Prenat Diagn 34:496–499CrossRefPubMed

28.

Norton ME, Jelliffe-Pawlowski LL, Currier RJ (2014) Chromosome abnormalities detected by current prenatal screening and noninvasive prenatal testing. Obstet Gynecol 124:979–986CrossRefPubMed

29.

Petersen OB, Vogel I, Ekelund C et al (2014) Potential diagnostic consequences of applying non-invasive prenatal testing: population-based study from a country with existing first-trimester screening. Ultrasound Obstet Gynecol 43:265–271CrossRefPubMed

30.

Song Y, Liu C, Qi H et al (2013) Noninvasive prenatal testing of fetal aneuploidies by massively parallel sequencing in a prospective Chinese population. Prenat Diagn 33:700–706CrossRefPubMed

31.

Bianchi DW, Parker RL, Wentworth J et al (2014) DNA sequencing versus standard prenatal aneuploidy screening. N Engl J Med 370:799–808CrossRefPubMed

32.

Mennuti MT, Cherry AM, Morrissette JJD, Dugoff L (2013) Is it time to sound an alarm about false-positive cell-free DNA testing for fetal aneuploidy? Am J Obstet Gynecol 209:415–419CrossRefPubMed

33.

Hook EB, Warburton D (2014) Turner syndrome revisited: review of new data supports the hypothesis that all viable 45,X cases are cryptic mosaics with a rescue cell line, implying an origin by mitotic loss. Hum Genet 133:417–424CrossRefPubMed

34.

Johnson A, Wapner RJ (1997) Mosaicism: implications for postnatal outcome. Curr Opin Obstet Gynecol 9:126–135CrossRefPubMed

35.

Futch T, Spinosa J, Bhatt S et al (2013) Initial clinical laboratory experience in noninvasive prenatal testing for fetal aneuploidy from maternal plasma DNA samples. Prenat Diagn 33:569–574CrossRefPubMedPubMedCentral

36.

Hall AL, Drendel HM, Verbrugge JL et al (2013) Positive cell-free fetal DNA testing for trisomy 13 reveals confined placental mosaicism. Genet Med 15:729–732CrossRefPubMed

37.

Pan M, Li FT, Li Y et al (2013) Discordant results between fetal karyotyping and non-invasive prenatal testing by maternal plasma sequencing in a case of uniparental disomy 21 due to trisomic rescue. Prenat Diagn 33:598–601CrossRefPubMed

38.

Landy HJ, Keith LG (1998) The vanishing twin: a review. Hum Reprod Update 4:177–183CrossRefPubMed

39.

Benson CB, Doubilet PM, Laks MP (1993) Outcome of twin gestations following sonographic demonstration of two heart beats in the first trimester. Ultrasound Obstet Gynecol 3:343–345CrossRefPubMed

40.

McAdoo S, Savage M, Hall MP et al (2013, October) a single nucleotide polymorphism-based approach to non-invasive prenatal testing identifies lingering cell-free fetal DNA in pregnancies with vanishing twins. Poster presented at the 63rd annual meeting of the American Society of Human Genetics, Boston

41.

Nicolaides KH, Syngelaki A, Gil M et al (2013) Validation of targeted sequencing of single-nucleotide polymorphisms for non-invasive prenatal detection of aneuploidy of chromosomes 13, 18, 21, X, and Y. Prenat Diagn 33:575–579CrossRefPubMed

42.

Lau TK, Jiang FM, Stevenson RJ et al (2013) Secondary findings from non-invasive prenatal testing for common fetal aneuploidies by whole genome sequencing as a clinical service. Prenat Diagn 33:602–608CrossRefPubMed

43.

Wang Y, Chen Y, Tian F et al (2014) Maternal mosaicism is a significant contributor to discordant sex chromosomal aneuploidies associated with noninvasive prenatal testing. Clin Chem 60:251–259CrossRefPubMed

44.

Stone JF, Sandberg AA (1995) Sex chromosome aneuploidy and aging. Mutat Res 338:107–113CrossRefPubMed

45.

Snyder MW, Simmons LE, Kitzman JO et al (2015) Copy-number variation and false positive prenatal aneuploidy screening results. N Engl J Med 372:1639–1645CrossRefPubMedPubMedCentral

46.

Bianchi DW, Chudova D, Sehnert AJ et al (2015) Noninvasive prenatal testing and incidental detection of occult maternal malignancies. JAMA 314:162–169CrossRefPubMed

47.

Osborne CM, Hardisty E, Devers P et al (2013) Discordant noninvasive prenatal testing results in a patient subsequently diagnosed with metastatic disease. Prenat Diagn 33:609–611CrossRefPubMed

48.

Snyder HL, Curnow KJ, Bhatt S et al (2016) Follow-up of multiple aneuploidies and single monosomies detected by noninvasive prenatal testing: implications for management and counseling. Prenat Diagn 36:203–209CrossRefPubMedPubMedCentral

49.

Bianchi DW, Parsa S, Bhatt S et al (2015) Fetal sex chromosome testing by maternal plasma DNA sequencing: clinical laboratory experience and biology. Obstet Gynecol 125:375–382CrossRefPubMed

50.

Gregg AR, Skotko BG, Benkendorf JL et al (2016) Noninvasive prenatal screening for fetal aneuploidy, 2016 update: a position statement of the American College of Medical Genetics and Genomics. Genet Med 18:1056–1065CrossRefPubMed

51.

Zhang H, Gao Y, Jiang F et al (2015) Non-invasive prenatal testing for trisomies 21, 18 and 13: clinical experience from 146,958 pregnancies. Ultrasound Obstet Gynecol 45:530–538CrossRefPubMed

52.

Hochstenbach R, Page-Christiaens GCML, van Oppen ACC et al (2015) Unexplained false negative results in noninvasive prenatal testing: two cases involving trisomies 13 and 18. Case Rep Genet 2015:926545PubMedPubMedCentral

53.

Smith M, Lewis KM, Holmes A et al (2014) A case of false negative NIPT for Down syndrome — lessons learned. Case Rep Genet 2014:823504PubMedPubMedCentral

54.

Chiu RWK, Akolekar R, Zheng YWL et al (2011) Non-invasive prenatal assessment of trisomy 21 by multiplexed maternal plasma DNA sequencing: large scale validity study. BMJ 342:c7401CrossRefPubMedPubMedCentral

55.

Nygren AOH, Dean J, Jensen TJ et al (2010) Quantification of fetal DNA by use of methylation-based DNA discrimination. Clin Chem 56:1627–1635CrossRefPubMed

56.

Kalousek DK, Barrett IJ, McGillivray BC (1989) Placental mosaicism and intrauterine survival of trisomies 13 and 18. Am J Hum Genet 44:338–343PubMedPubMedCentral

57.

Rava RP, Srinivasan A, Sehnert AJ et al (2014) Circulating fetal cell-free DNA fractions differ in autosomal aneuploidies and monosomy X. Clin Chem 60:243–250CrossRefPubMed

58.

Palomaki GE, Kloza EM, Lambert-Messerlian GM et al (2015) Circulating cell free DNA testing: are some test failures informative? Prenat Diagn 35:289–293CrossRefPubMed

59.

Dunham A, Matthews LH, Burton J et al (2004) The DNA sequence and analysis of human chromosome 13. Nature 428:522–528CrossRefPubMedPubMedCentral

60.

Nicolaides KH, Syngelaki A, del Mar GM et al (2014) Prenatal detection of fetal triploidy from cell-free DNA testing in maternal blood. Fetal Diagn Ther 35:212–217CrossRefPubMed

61.

Ashoor G, Syngelaki A, Poon LCY et al (2013) Fetal fraction in maternal plasma cell-free DNA at 11-13 weeks’ gestation: relation to maternal and fetal characteristics. Ultrasound Obstet Gynecol 41:26–32CrossRefPubMed

62.

Williams J 3rd, Rad S, Beauchamp S et al (2015) Utilization of noninvasive prenatal testing: impact on referrals for diagnostic testing. Am J Obstet Gynecol 213:102.e1–102.e6CrossRef

63.

Bevilacqua E, Gil MM, Nicolaides KH et al (2015) Performance of screening for aneuploidies by cell-free DNA analysis of maternal blood in twin pregnancies. Ultrasound Obstet Gynecol 45:61–66CrossRefPubMed

64.

Sarno L, Revello R, Hanson E et al (2016) Prospective first-trimester screening for trisomies by cell-free DNA testing of maternal blood in twin pregnancy. Ultrasound Obstet Gynecol 47:705–711CrossRefPubMed

65.

Haque IS, Lazarin GA, Kang HP et al (2016) Modeled fetal risk of genetic diseases identified by expanded carrier screening. JAMA 316:734–742CrossRefPubMed

66.

Allyse M, Chandrasekharan S (2015) Too much, too soon?: commercial provision of noninvasive prenatal screening for subchromosomal abnormalities and beyond. Genet Med 17:958–961CrossRefPubMedPubMedCentral

67.

Vora NL, BM OB (2014) Noninvasive prenatal testing for microdeletion syndromes and expanded trisomies: proceed with caution. Obstet Gynecol 123:1097–1099CrossRefPubMed

68.

Gross SJ, Stosic M, McDonald-McGinn DM et al (2016) Clinical experience with single-nucleotide polymorphism-based non-invasive prenatal screening for 22q11.2 deletion syndrome. Ultrasound Obstet Gynecol 47:177–183CrossRefPubMedPubMedCentral

69.

Society for Maternal-Fetal Medicine (SMFM), Norton ME, Biggio JR et al (2017) The role of ultrasound in women who undergo cell-free DNA screening. Am J Obstet Gynecol 216:B2–B7CrossRef

70.

Lefkowitz RB, Tynan JA, Liu T et al (2016) Clinical validation of a noninvasive prenatal test for genomewide detection of fetal copy number variants. Am J Obstet Gynecol 215:227.e1–227.e16CrossRef

71.

Norton ME, Jacobsson B, Swamy GK et al (2015) Cell-free DNA analysis for noninvasive examination of trisomy. N Engl J Med 372:1589–1597CrossRefPubMed

72.

Norton ME, Baer RJ, Wapner RJ et al (2016) Cell-free DNA vs sequential screening for the detection of fetal chromosomal abnormalities. Am J Obstet Gynecol 214:727.e1–727.e6CrossRef

73.

Ledbetter DH, Zachary JM, Simpson JL et al (1992) Cytogenetic results from the U.S. collaborative study on CVS. Prenat Diagn 12:317–345CrossRefPubMed

74.

de Graaf G, Buckley F, Skotko BG (2015) Estimates of the live births, natural losses, and elective terminations with Down syndrome in the United States. Am J Med Genet A 167A:756–767CrossRefPubMed

75.

Reimers RM, Dobson L, Hanmer K et al (2016) Pregnancy outcomes for trisomy 21 following NIPT, CVS, and amniocentesis. In: proceedings of the 36th annual meeting of the Society for Maternal Fetal Medicine. Am J Obstet Gynecol 214:S320

76.

Comstock CH, Malone FD, Ball RH et al (2006) Is there a nuchal translucency millimeter measurement above which there is no added benefit from first trimester serum screening? Am J Obstet Gynecol 195:843–847CrossRefPubMed

77.

Pandya PP, Snijders RJ, Johnson S et al (1995) Natural history of trisomy 21 fetuses with increased nuchal translucency thickness. Ultrasound Obstet Gynecol 5:381–383CrossRefPubMed

78.

Savva GM, Morris JK, Mutton DE et al (2006) Maternal age-specific fetal loss rates in Down syndrome pregnancies. Prenat Diagn 26:499–504CrossRefPubMed

79.

Wessels MW, Los FJ, Frohn-Mulder IME et al (2003) Poor outcome in Down syndrome fetuses with cardiac anomalies or growth retardation. Am J Med Genet A 116A:147–151CrossRefPubMed

80.

Guseh SH, Little SE, Bennett K et al (2017) Antepartum management and obstetric outcomes among pregnancies with Down syndrome from diagnosis to delivery. Prenat Diagn. doi:10.1002/pd.5054

81.

Mutton D, Alberman E, Hook EB (1996) Cytogenetic and epidemiological findings in Down syndrome, England and Wales 1989 to 1993. National Down Syndrome Cytogenetic Register and the Association of Clinical Cytogeneticists. J Med Genet 33:387–394CrossRefPubMedPubMedCentral

82.

Morris JK, Alberman E, Mutton D (2012) Cytogenetic and epidemiological findings in Down syndrome: England and Wales 1989–2009. Am J Med Genet A 158A:1151–1157CrossRefPubMed

Titel: Have we done our last amniocentesis? Updates on cell-free DNA for Down syndrome screening
verfasst von: Kathryn J. Gray
Louise E. Wilkins-Haug
Publikationsdatum: 01.04.2018
Verlag: Springer Berlin Heidelberg
Erschienen in: Pediatric Radiology / Ausgabe 4/2018
Print ISSN: 0301-0449
Elektronische ISSN: 1432-1998
DOI: https://doi.org/10.1007/s00247-017-3958-y

Neu im Fachgebiet Radiologie

18.04.2024 | Pädiatrische Notfallmedizin | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Have we done our last amniocentesis? Updates on cell-free DNA for Down syndrome screening

Abstract

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Update Radiologie

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Fetal anterior abdominal wall defects: prenatal imaging by magnetic resonance imaging

Fetal neuroimaging: an update on technical advances and clinical findings

Hermes

Team counseling in prenatal evaluation: the partnership of the radiologist and genetic counselor

Spectrum of cerebral arterial and venous abnormalities in Alagille syndrome

Role of interventional radiology in managing pediatric liver tumors

Neu im Fachgebiet Radiologie

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Studie bestätigt Potenzial von KI in der Radiologie

Update Radiologie